Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Junshi Biosciences (688180 CH)
Watchlist
42
Analysis
Health Care
•
China
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Shanghai Junshi Biosciences
•
14 Jun 2022 08:30
Shanghai Junshi Bioscience Placement- Junshi Is Having a Hard Time, with Lower than Expected Returns
Junshi's Achilles heel is lack of cash and is in difficult time. PD-1/COVID-19 products can't relieve cashflow pressure.The uncertain outlook/macro...
Xinyao (Criss) Wang
Follow
289 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
02 Apr 2022 19:32
Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval
Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....
Tina Banerjee
Follow
317 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
10 Jan 2022 09:05
Shanghai Junshi Bioscience (1877.HK/688180.CH) - Behind the “break Up” with AstraZeneca
The insight analyzed Junshi in terms of the potential reasons behind the termination of PD-1 commercialization partnership with AstraZeneca, the...
Xinyao (Criss) Wang
Follow
306 Views
Share
bearish
•
Shanghai Junshi Biosciences
•
24 Mar 2021 09:13
Shanghai Junshi Bioscience - Here Are the Challenges
The article analyzed the concerns and challenges that Junshi has to face in terms of PD-1, COVID-19 antibody drug, other products in the pipeline...
Xinyao (Criss) Wang
Follow
203 Views
Share
bullish
•
Shanghai Junshi Biosciences
•
27 Feb 2021 18:29
STAR Board - STAR50 Index Rebalance: Another BIG One
There are 5 changes to the STAR50 index as a part of the March review. Estimated one-way turnover is 8.93% and we expect the inclusions to...
Brian Freitas
Follow
409 Views
Share
First
Previous
4
5
6
7
8
9
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.1
x